Arafat Shabbir
Role not yet determined Is this you? Add your title
Also affiliated: Yale New Haven Hospital (2022–2023); Guthrie Foundation (2022); Mount Sinai Medical Center (2022); Regional Medical Center (2026); Columbia University (2022)
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Arafat Shabbir's research focuses on cancer biology and treatment, with a particular emphasis on genetic alterations and therapeutic strategies. His work includes investigating the role of RET alterations in various cancers and exploring the efficacy of targeted therapies and immunotherapies. Shabbir has also contributed to the literature on specific cancer types, such as extranodal diffuse large B-cell lymphoma and neuroendocrine carcinomas.
His research extends to systematic reviews and meta-analyses of emerging treatment modalities. This includes evaluating CAR-T cell therapy for prostate cancer and assessing the outcomes of 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer, as well as its efficacy in metastatic hormone-sensitive prostate cancer. Shabbir's publications also touch upon the incidence of Clostridioides difficile infection in stem cell transplant recipients.
Metrics
- h-index: 2
- Publications: 8
- Citations: 25
Selected Publications
-
Role of CAR-T cell therapy in prostate cancer: A systematic review and meta-analysis. (2026)
-
Persistence of aggressive biology: Outcomes of <sup>177</sup> Lu-PSMA-617 in <i>BRCA</i> -altered mCRPC—Systematic review and meta-analysis. (2026)
-
Efficacy of Lu-PSMA–based treatment strategies in metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis. (2026)
Collaboration Network
Top Collaborators
- Efficacy of Lu-PSMA–based treatment strategies in metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis.
- Persistence of aggressive biology: Outcomes of <sup>177</sup> Lu-PSMA-617 in <i>BRCA</i> -altered mCRPC—Systematic review and meta-analysis.
- Role of CAR-T cell therapy in prostate cancer: A systematic review and meta-analysis.
- Efficacy of Lu-PSMA–based treatment strategies in metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis.
- Role of CAR-T cell therapy in prostate cancer: A systematic review and meta-analysis.
- Efficacy of Lu-PSMA–based treatment strategies in metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis.
- Role of CAR-T cell therapy in prostate cancer: A systematic review and meta-analysis.
- Persistence of aggressive biology: Outcomes of <sup>177</sup> Lu-PSMA-617 in <i>BRCA</i> -altered mCRPC—Systematic review and meta-analysis.
- Role of CAR-T cell therapy in prostate cancer: A systematic review and meta-analysis.
- Efficacy of Lu-PSMA–based treatment strategies in metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis.
- Efficacy of Lu-PSMA–based treatment strategies in metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis.
- Efficacy of Lu-PSMA–based treatment strategies in metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis.
- Efficacy of Lu-PSMA–based treatment strategies in metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis.
- Efficacy of Lu-PSMA–based treatment strategies in metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis.
- Persistence of aggressive biology: Outcomes of <sup>177</sup> Lu-PSMA-617 in <i>BRCA</i> -altered mCRPC—Systematic review and meta-analysis.
- Persistence of aggressive biology: Outcomes of <sup>177</sup> Lu-PSMA-617 in <i>BRCA</i> -altered mCRPC—Systematic review and meta-analysis.
- Persistence of aggressive biology: Outcomes of <sup>177</sup> Lu-PSMA-617 in <i>BRCA</i> -altered mCRPC—Systematic review and meta-analysis.
- Persistence of aggressive biology: Outcomes of <sup>177</sup> Lu-PSMA-617 in <i>BRCA</i> -altered mCRPC—Systematic review and meta-analysis.
- Persistence of aggressive biology: Outcomes of <sup>177</sup> Lu-PSMA-617 in <i>BRCA</i> -altered mCRPC—Systematic review and meta-analysis.
- Role of CAR-T cell therapy in prostate cancer: A systematic review and meta-analysis.
Similar Researchers
Based on overlapping research topics